drugset / Trial / NCT02468414
TARGTEPO Treatment for Anemia in PD US Trial
Phase 2
Terminated
3 enrolled
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
Timeline
- Start
- 2015-06
- Primary completion
- 2016-05
- Completion
- 2016-09
Outcome
Outcome not reported
Stopped: “No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due to the Sponsor's decision to discontinue study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TARGTEPO | Unknown | 18 iu/kg | — |
| Subject | TARGTEPO | Unknown | 25 iu/kg | — |
| Subject | TARGTEPO | Unknown | 35 iu/kg | — |
| Subject | TARGTEPO | Unknown | 45 iu/kg | — |